ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Human Hepatitis B Immunoglobulin Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-31R4120
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Human Hepatitis B Immunoglobulin Market Insights and Forecast to 2028
BUY CHAPTERS

Global Human Hepatitis B Immunoglobulin Market Research Report 2025

Code: QYRE-Auto-31R4120
Report
September 2025
Pages:95
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Baxter
CSL Limited
Bayer
Grifols S A
China Biologic
Tiantan Biologic
Shuanglin Bio-pharmacy
Sichuan Yuanda Shuyang
Boya Bio-pharmaceutical
Shanghai Institute of Biological
Octapharma
Octapharma AG
Shanghai Raas
Hualan Biological

Human Hepatitis B Immunoglobulin Market

The global market for Human Hepatitis B Immunoglobulin was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Human hepatitis B immunoglobulin (HBIG) is a blood-derived product that contains antibodies against the hepatitis B virus (HBV). HBIG is used for both the prevention and treatment of hepatitis B infection. Here is an overview of the prospect for human hepatitis B immunoglobulin:
1. Prevention of hepatitis B transmission: HBIG is administered to individuals at high risk of HBV transmission, such as newborns from HBV-infected mothers, healthcare workers exposed to HBV-positive blood, and individuals who have had close contact with someone infected with HBV. It provides passive immunity by rapidly increasing antibody levels against HBV, reducing the risk of infection.
2. Post-exposure prophylaxis: HBIG can be given as part of post-exposure prophylaxis, especially for individuals who have recently been exposed to HBV and have not been vaccinated or who have low or no immune response to HBV vaccines. It provides immediate protection against HBV infection while the body mounts its immune response.
3. Treatment of acute hepatitis B: HBIG can be used in the treatment of acute hepatitis B infection, especially in cases with severe symptoms or complications. It helps to reduce viral replication, control the infection, and prevent further damage to the liver. HBIG may be used in combination with antiviral medications for optimal treatment outcomes.
4. Pre-transplant and post-transplant prophylaxis: HBIG is often used in individuals undergoing liver transplantation for HBV-related liver disease. Pre-transplant HBIG administration aims to reduce viral load and prevent HBV re-infection of the transplanted liver. Post-transplant HBIG is given to suppress viral replication and provide long-term protection against HBV recurrence.
5. Long-term prophylaxis for chronic hepatitis B: In some cases of chronic hepatitis B infection, long-term HBIG administration may be recommended to maintain protective levels of antibodies and prevent disease progression or reactivation. This is often combined with antiviral medications to achieve the best outcomes.
6. Safety and efficacy: HBIG is derived from blood plasma and undergoes rigorous screening and testing to ensure safety and efficacy. However, as with any blood-derived product, there may be a minimal risk of transmitting infectious agents. The benefits of HBIG in preventing or treating HBV infection usually outweigh the potential risks.
7. Ongoing research and development: Research is ongoing to improve the efficacy, safety, and convenience of HBIG administration. This includes the development of recombinant HBIG and alternative dosing regimens to reduce the volume and frequency of administration.
Overall, the prospect for human hepatitis B immunoglobulin lies in its vital role in preventing HBV transmission, providing immediate protection after exposure, treating acute infection, and managing chronic hepatitis B. Continued research and development will further enhance the benefits and applicability of HBIG, ensuring improved outcomes for individuals at risk of or infected with HBV.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Human Hepatitis B Immunoglobulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Hepatitis B Immunoglobulin.
The Human Hepatitis B Immunoglobulin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Hepatitis B Immunoglobulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Hepatitis B Immunoglobulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Human Hepatitis B Immunoglobulin Market Report

Report Metric Details
Report Name Human Hepatitis B Immunoglobulin Market
Segment by Type
  • 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
  • 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
  • 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
Segment by Application
  • Hepatitis B Carrier
  • Hepatitis B Close Contacts
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Baxter, CSL, Bayer, Grifols, Octapharma, Shanghai RAAS, Hualan Biological, China Biologic, Tiantan Biologic, Shuanglin Bio-pharmacy, Sichuan Yuanda Shuyang, Boya Bio-pharmaceutical, Shanghai Institute of Biological
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Human Hepatitis B Immunoglobulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Human Hepatitis B Immunoglobulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Human Hepatitis B Immunoglobulin Market report?

Ans: The main players in the Human Hepatitis B Immunoglobulin Market are Baxter, CSL, Bayer, Grifols, Octapharma, Shanghai RAAS, Hualan Biological, China Biologic, Tiantan Biologic, Shuanglin Bio-pharmacy, Sichuan Yuanda Shuyang, Boya Bio-pharmaceutical, Shanghai Institute of Biological

What are the Application segmentation covered in the Human Hepatitis B Immunoglobulin Market report?

Ans: The Applications covered in the Human Hepatitis B Immunoglobulin Market report are Hepatitis B Carrier, Hepatitis B Close Contacts

What are the Type segmentation covered in the Human Hepatitis B Immunoglobulin Market report?

Ans: The Types covered in the Human Hepatitis B Immunoglobulin Market report are 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG), 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG), 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)

1 Human Hepatitis B Immunoglobulin Market Overview
1.1 Product Definition
1.2 Human Hepatitis B Immunoglobulin by Type
1.2.1 Global Human Hepatitis B Immunoglobulin Market Value Comparison by Type (2024 VS 2031)
1.2.2 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
1.2.3 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
1.2.4 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
1.3 Human Hepatitis B Immunoglobulin by Application
1.3.1 Global Human Hepatitis B Immunoglobulin Market Value by Application (2024 VS 2031)
1.3.2 Hepatitis B Carrier
1.3.3 Hepatitis B Close Contacts
1.4 Global Human Hepatitis B Immunoglobulin Market Size Estimates and Forecasts
1.4.1 Global Human Hepatitis B Immunoglobulin Revenue 2020-2031
1.4.2 Global Human Hepatitis B Immunoglobulin Sales 2020-2031
1.4.3 Global Human Hepatitis B Immunoglobulin Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Human Hepatitis B Immunoglobulin Market Competition by Manufacturers
2.1 Global Human Hepatitis B Immunoglobulin Sales Market Share by Manufacturers (2020-2025)
2.2 Global Human Hepatitis B Immunoglobulin Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Human Hepatitis B Immunoglobulin Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Human Hepatitis B Immunoglobulin, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Hepatitis B Immunoglobulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Hepatitis B Immunoglobulin, Product Type & Application
2.7 Global Key Manufacturers of Human Hepatitis B Immunoglobulin, Date of Enter into This Industry
2.8 Global Human Hepatitis B Immunoglobulin Market Competitive Situation and Trends
2.8.1 Global Human Hepatitis B Immunoglobulin Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Human Hepatitis B Immunoglobulin Players Market Share by Revenue
2.8.3 Global Human Hepatitis B Immunoglobulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Hepatitis B Immunoglobulin Market Scenario by Region
3.1 Global Human Hepatitis B Immunoglobulin Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Human Hepatitis B Immunoglobulin Sales by Region: 2020-2031
3.2.1 Global Human Hepatitis B Immunoglobulin Sales by Region: 2020-2025
3.2.2 Global Human Hepatitis B Immunoglobulin Sales by Region: 2026-2031
3.3 Global Human Hepatitis B Immunoglobulin Revenue by Region: 2020-2031
3.3.1 Global Human Hepatitis B Immunoglobulin Revenue by Region: 2020-2025
3.3.2 Global Human Hepatitis B Immunoglobulin Revenue by Region: 2026-2031
3.4 North America Human Hepatitis B Immunoglobulin Market Facts & Figures by Country
3.4.1 North America Human Hepatitis B Immunoglobulin Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Human Hepatitis B Immunoglobulin Sales by Country (2020-2031)
3.4.3 North America Human Hepatitis B Immunoglobulin Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Hepatitis B Immunoglobulin Market Facts & Figures by Country
3.5.1 Europe Human Hepatitis B Immunoglobulin Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Human Hepatitis B Immunoglobulin Sales by Country (2020-2031)
3.5.3 Europe Human Hepatitis B Immunoglobulin Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Hepatitis B Immunoglobulin Market Facts & Figures by Region
3.6.1 Asia Pacific Human Hepatitis B Immunoglobulin Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Human Hepatitis B Immunoglobulin Sales by Region (2020-2031)
3.6.3 Asia Pacific Human Hepatitis B Immunoglobulin Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Human Hepatitis B Immunoglobulin Market Facts & Figures by Country
3.7.1 Latin America Human Hepatitis B Immunoglobulin Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Human Hepatitis B Immunoglobulin Sales by Country (2020-2031)
3.7.3 Latin America Human Hepatitis B Immunoglobulin Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Hepatitis B Immunoglobulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Hepatitis B Immunoglobulin Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Human Hepatitis B Immunoglobulin Sales by Country (2020-2031)
3.8.3 Middle East and Africa Human Hepatitis B Immunoglobulin Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Hepatitis B Immunoglobulin Sales by Type (2020-2031)
4.1.1 Global Human Hepatitis B Immunoglobulin Sales by Type (2020-2025)
4.1.2 Global Human Hepatitis B Immunoglobulin Sales by Type (2026-2031)
4.1.3 Global Human Hepatitis B Immunoglobulin Sales Market Share by Type (2020-2031)
4.2 Global Human Hepatitis B Immunoglobulin Revenue by Type (2020-2031)
4.2.1 Global Human Hepatitis B Immunoglobulin Revenue by Type (2020-2025)
4.2.2 Global Human Hepatitis B Immunoglobulin Revenue by Type (2026-2031)
4.2.3 Global Human Hepatitis B Immunoglobulin Revenue Market Share by Type (2020-2031)
4.3 Global Human Hepatitis B Immunoglobulin Price by Type (2020-2031)
5 Segment by Application
5.1 Global Human Hepatitis B Immunoglobulin Sales by Application (2020-2031)
5.1.1 Global Human Hepatitis B Immunoglobulin Sales by Application (2020-2025)
5.1.2 Global Human Hepatitis B Immunoglobulin Sales by Application (2026-2031)
5.1.3 Global Human Hepatitis B Immunoglobulin Sales Market Share by Application (2020-2031)
5.2 Global Human Hepatitis B Immunoglobulin Revenue by Application (2020-2031)
5.2.1 Global Human Hepatitis B Immunoglobulin Revenue by Application (2020-2025)
5.2.2 Global Human Hepatitis B Immunoglobulin Revenue by Application (2026-2031)
5.2.3 Global Human Hepatitis B Immunoglobulin Revenue Market Share by Application (2020-2031)
5.3 Global Human Hepatitis B Immunoglobulin Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Baxter
6.1.1 Baxter Company Information
6.1.2 Baxter Description and Business Overview
6.1.3 Baxter Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Baxter Human Hepatitis B Immunoglobulin Product Portfolio
6.1.5 Baxter Recent Developments/Updates
6.2 CSL
6.2.1 CSL Company Information
6.2.2 CSL Description and Business Overview
6.2.3 CSL Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.2.4 CSL Human Hepatitis B Immunoglobulin Product Portfolio
6.2.5 CSL Recent Developments/Updates
6.3 Bayer
6.3.1 Bayer Company Information
6.3.2 Bayer Description and Business Overview
6.3.3 Bayer Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Bayer Human Hepatitis B Immunoglobulin Product Portfolio
6.3.5 Bayer Recent Developments/Updates
6.4 Grifols
6.4.1 Grifols Company Information
6.4.2 Grifols Description and Business Overview
6.4.3 Grifols Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Grifols Human Hepatitis B Immunoglobulin Product Portfolio
6.4.5 Grifols Recent Developments/Updates
6.5 Octapharma
6.5.1 Octapharma Company Information
6.5.2 Octapharma Description and Business Overview
6.5.3 Octapharma Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Octapharma Human Hepatitis B Immunoglobulin Product Portfolio
6.5.5 Octapharma Recent Developments/Updates
6.6 Shanghai RAAS
6.6.1 Shanghai RAAS Company Information
6.6.2 Shanghai RAAS Description and Business Overview
6.6.3 Shanghai RAAS Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Shanghai RAAS Human Hepatitis B Immunoglobulin Product Portfolio
6.6.5 Shanghai RAAS Recent Developments/Updates
6.7 Hualan Biological
6.7.1 Hualan Biological Company Information
6.7.2 Hualan Biological Description and Business Overview
6.7.3 Hualan Biological Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Hualan Biological Human Hepatitis B Immunoglobulin Product Portfolio
6.7.5 Hualan Biological Recent Developments/Updates
6.8 China Biologic
6.8.1 China Biologic Company Information
6.8.2 China Biologic Description and Business Overview
6.8.3 China Biologic Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.8.4 China Biologic Human Hepatitis B Immunoglobulin Product Portfolio
6.8.5 China Biologic Recent Developments/Updates
6.9 Tiantan Biologic
6.9.1 Tiantan Biologic Company Information
6.9.2 Tiantan Biologic Description and Business Overview
6.9.3 Tiantan Biologic Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Tiantan Biologic Human Hepatitis B Immunoglobulin Product Portfolio
6.9.5 Tiantan Biologic Recent Developments/Updates
6.10 Shuanglin Bio-pharmacy
6.10.1 Shuanglin Bio-pharmacy Company Information
6.10.2 Shuanglin Bio-pharmacy Description and Business Overview
6.10.3 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Product Portfolio
6.10.5 Shuanglin Bio-pharmacy Recent Developments/Updates
6.11 Sichuan Yuanda Shuyang
6.11.1 Sichuan Yuanda Shuyang Company Information
6.11.2 Sichuan Yuanda Shuyang Description and Business Overview
6.11.3 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Product Portfolio
6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.12 Boya Bio-pharmaceutical
6.12.1 Boya Bio-pharmaceutical Company Information
6.12.2 Boya Bio-pharmaceutical Description and Business Overview
6.12.3 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Product Portfolio
6.12.5 Boya Bio-pharmaceutical Recent Developments/Updates
6.13 Shanghai Institute of Biological
6.13.1 Shanghai Institute of Biological Company Information
6.13.2 Shanghai Institute of Biological Description and Business Overview
6.13.3 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Product Portfolio
6.13.5 Shanghai Institute of Biological Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Hepatitis B Immunoglobulin Industry Chain Analysis
7.2 Human Hepatitis B Immunoglobulin Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Hepatitis B Immunoglobulin Production Mode & Process Analysis
7.4 Human Hepatitis B Immunoglobulin Sales and Marketing
7.4.1 Human Hepatitis B Immunoglobulin Sales Channels
7.4.2 Human Hepatitis B Immunoglobulin Distributors
7.5 Human Hepatitis B Immunoglobulin Customer Analysis
8 Human Hepatitis B Immunoglobulin Market Dynamics
8.1 Human Hepatitis B Immunoglobulin Industry Trends
8.2 Human Hepatitis B Immunoglobulin Market Drivers
8.3 Human Hepatitis B Immunoglobulin Market Challenges
8.4 Human Hepatitis B Immunoglobulin Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Baxter
CSL Limited
Bayer
Grifols S A
China Biologic
Tiantan Biologic
Shuanglin Bio-pharmacy
Sichuan Yuanda Shuyang
Boya Bio-pharmaceutical
Shanghai Institute of Biological
Octapharma
Octapharma AG
Shanghai Raas
Hualan Biological
List of Tables
 Table 1. Global Human Hepatitis B Immunoglobulin Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Human Hepatitis B Immunoglobulin Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Human Hepatitis B Immunoglobulin Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Human Hepatitis B Immunoglobulin Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Human Hepatitis B Immunoglobulin Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Human Hepatitis B Immunoglobulin Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Human Hepatitis B Immunoglobulin Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Human Hepatitis B Immunoglobulin Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Human Hepatitis B Immunoglobulin, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Human Hepatitis B Immunoglobulin, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Human Hepatitis B Immunoglobulin, Product Type & Application
 Table 12. Global Key Manufacturers of Human Hepatitis B Immunoglobulin, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Human Hepatitis B Immunoglobulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Hepatitis B Immunoglobulin as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Human Hepatitis B Immunoglobulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Human Hepatitis B Immunoglobulin Sales by Region (2020-2025) & (K Units)
 Table 18. Global Human Hepatitis B Immunoglobulin Sales Market Share by Region (2020-2025)
 Table 19. Global Human Hepatitis B Immunoglobulin Sales by Region (2026-2031) & (K Units)
 Table 20. Global Human Hepatitis B Immunoglobulin Sales Market Share by Region (2026-2031)
 Table 21. Global Human Hepatitis B Immunoglobulin Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Region (2020-2025)
 Table 23. Global Human Hepatitis B Immunoglobulin Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Region (2026-2031)
 Table 25. North America Human Hepatitis B Immunoglobulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Human Hepatitis B Immunoglobulin Sales by Country (2020-2025) & (K Units)
 Table 27. North America Human Hepatitis B Immunoglobulin Sales by Country (2026-2031) & (K Units)
 Table 28. North America Human Hepatitis B Immunoglobulin Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Human Hepatitis B Immunoglobulin Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Human Hepatitis B Immunoglobulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Human Hepatitis B Immunoglobulin Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Human Hepatitis B Immunoglobulin Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Human Hepatitis B Immunoglobulin Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Human Hepatitis B Immunoglobulin Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Human Hepatitis B Immunoglobulin Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Human Hepatitis B Immunoglobulin Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Human Hepatitis B Immunoglobulin Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Human Hepatitis B Immunoglobulin Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Human Hepatitis B Immunoglobulin Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Human Hepatitis B Immunoglobulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Human Hepatitis B Immunoglobulin Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Human Hepatitis B Immunoglobulin Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Human Hepatitis B Immunoglobulin Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Human Hepatitis B Immunoglobulin Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Human Hepatitis B Immunoglobulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Human Hepatitis B Immunoglobulin Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Human Hepatitis B Immunoglobulin Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Human Hepatitis B Immunoglobulin Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Human Hepatitis B Immunoglobulin Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Human Hepatitis B Immunoglobulin Sales (K Units) by Type (2020-2025)
 Table 51. Global Human Hepatitis B Immunoglobulin Sales (K Units) by Type (2026-2031)
 Table 52. Global Human Hepatitis B Immunoglobulin Sales Market Share by Type (2020-2025)
 Table 53. Global Human Hepatitis B Immunoglobulin Sales Market Share by Type (2026-2031)
 Table 54. Global Human Hepatitis B Immunoglobulin Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Human Hepatitis B Immunoglobulin Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Type (2020-2025)
 Table 57. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Type (2026-2031)
 Table 58. Global Human Hepatitis B Immunoglobulin Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Human Hepatitis B Immunoglobulin Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Human Hepatitis B Immunoglobulin Sales (K Units) by Application (2020-2025)
 Table 61. Global Human Hepatitis B Immunoglobulin Sales (K Units) by Application (2026-2031)
 Table 62. Global Human Hepatitis B Immunoglobulin Sales Market Share by Application (2020-2025)
 Table 63. Global Human Hepatitis B Immunoglobulin Sales Market Share by Application (2026-2031)
 Table 64. Global Human Hepatitis B Immunoglobulin Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Human Hepatitis B Immunoglobulin Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Application (2020-2025)
 Table 67. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Application (2026-2031)
 Table 68. Global Human Hepatitis B Immunoglobulin Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Human Hepatitis B Immunoglobulin Price (USD/Unit) by Application (2026-2031)
 Table 70. Baxter Company Information
 Table 71. Baxter Description and Business Overview
 Table 72. Baxter Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Baxter Human Hepatitis B Immunoglobulin Product
 Table 74. Baxter Recent Developments/Updates
 Table 75. CSL Company Information
 Table 76. CSL Description and Business Overview
 Table 77. CSL Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. CSL Human Hepatitis B Immunoglobulin Product
 Table 79. CSL Recent Developments/Updates
 Table 80. Bayer Company Information
 Table 81. Bayer Description and Business Overview
 Table 82. Bayer Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Bayer Human Hepatitis B Immunoglobulin Product
 Table 84. Bayer Recent Developments/Updates
 Table 85. Grifols Company Information
 Table 86. Grifols Description and Business Overview
 Table 87. Grifols Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Grifols Human Hepatitis B Immunoglobulin Product
 Table 89. Grifols Recent Developments/Updates
 Table 90. Octapharma Company Information
 Table 91. Octapharma Description and Business Overview
 Table 92. Octapharma Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Octapharma Human Hepatitis B Immunoglobulin Product
 Table 94. Octapharma Recent Developments/Updates
 Table 95. Shanghai RAAS Company Information
 Table 96. Shanghai RAAS Description and Business Overview
 Table 97. Shanghai RAAS Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Shanghai RAAS Human Hepatitis B Immunoglobulin Product
 Table 99. Shanghai RAAS Recent Developments/Updates
 Table 100. Hualan Biological Company Information
 Table 101. Hualan Biological Description and Business Overview
 Table 102. Hualan Biological Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Hualan Biological Human Hepatitis B Immunoglobulin Product
 Table 104. Hualan Biological Recent Developments/Updates
 Table 105. China Biologic Company Information
 Table 106. China Biologic Description and Business Overview
 Table 107. China Biologic Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. China Biologic Human Hepatitis B Immunoglobulin Product
 Table 109. China Biologic Recent Developments/Updates
 Table 110. Tiantan Biologic Company Information
 Table 111. Tiantan Biologic Description and Business Overview
 Table 112. Tiantan Biologic Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. Tiantan Biologic Human Hepatitis B Immunoglobulin Product
 Table 114. Tiantan Biologic Recent Developments/Updates
 Table 115. Shuanglin Bio-pharmacy Company Information
 Table 116. Shuanglin Bio-pharmacy Description and Business Overview
 Table 117. Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Product
 Table 119. Shuanglin Bio-pharmacy Recent Developments/Updates
 Table 120. Sichuan Yuanda Shuyang Company Information
 Table 121. Sichuan Yuanda Shuyang Description and Business Overview
 Table 122. Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 123. Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Product
 Table 124. Sichuan Yuanda Shuyang Recent Developments/Updates
 Table 125. Boya Bio-pharmaceutical Company Information
 Table 126. Boya Bio-pharmaceutical Description and Business Overview
 Table 127. Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 128. Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Product
 Table 129. Boya Bio-pharmaceutical Recent Developments/Updates
 Table 130. Shanghai Institute of Biological Company Information
 Table 131. Shanghai Institute of Biological Description and Business Overview
 Table 132. Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 133. Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Product
 Table 134. Shanghai Institute of Biological Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Human Hepatitis B Immunoglobulin Distributors List
 Table 138. Human Hepatitis B Immunoglobulin Customers List
 Table 139. Human Hepatitis B Immunoglobulin Market Trends
 Table 140. Human Hepatitis B Immunoglobulin Market Drivers
 Table 141. Human Hepatitis B Immunoglobulin Market Challenges
 Table 142. Human Hepatitis B Immunoglobulin Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Human Hepatitis B Immunoglobulin
 Figure 2. Global Human Hepatitis B Immunoglobulin Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Human Hepatitis B Immunoglobulin Market Share by Type: 2024 & 2031
 Figure 4. 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Product Picture
 Figure 5. 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Product Picture
 Figure 6. 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Product Picture
 Figure 7. Global Human Hepatitis B Immunoglobulin Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Human Hepatitis B Immunoglobulin Market Share by Application: 2024 & 2031
 Figure 9. Hepatitis B Carrier
 Figure 10. Hepatitis B Close Contacts
 Figure 11. Global Human Hepatitis B Immunoglobulin Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Human Hepatitis B Immunoglobulin Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Human Hepatitis B Immunoglobulin Sales (2020-2031) & (K Units)
 Figure 14. Global Human Hepatitis B Immunoglobulin Average Price (USD/Unit) & (2020-2031)
 Figure 15. Human Hepatitis B Immunoglobulin Report Years Considered
 Figure 16. Human Hepatitis B Immunoglobulin Sales Share by Manufacturers in 2024
 Figure 17. Global Human Hepatitis B Immunoglobulin Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Human Hepatitis B Immunoglobulin Players: Market Share by Revenue in Human Hepatitis B Immunoglobulin in 2024
 Figure 19. Human Hepatitis B Immunoglobulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Human Hepatitis B Immunoglobulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Human Hepatitis B Immunoglobulin Sales Market Share by Country (2020-2031)
 Figure 22. North America Human Hepatitis B Immunoglobulin Revenue Market Share by Country (2020-2031)
 Figure 23. U.S. Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Human Hepatitis B Immunoglobulin Sales Market Share by Country (2020-2031)
 Figure 26. Europe Human Hepatitis B Immunoglobulin Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Human Hepatitis B Immunoglobulin Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Human Hepatitis B Immunoglobulin Revenue Market Share by Region (2020-2031)
 Figure 34. China Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Human Hepatitis B Immunoglobulin Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Human Hepatitis B Immunoglobulin Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Human Hepatitis B Immunoglobulin Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Human Hepatitis B Immunoglobulin Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Human Hepatitis B Immunoglobulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Human Hepatitis B Immunoglobulin by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Human Hepatitis B Immunoglobulin by Type (2020-2031)
 Figure 55. Global Human Hepatitis B Immunoglobulin Price (USD/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Human Hepatitis B Immunoglobulin by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Human Hepatitis B Immunoglobulin by Application (2020-2031)
 Figure 58. Global Human Hepatitis B Immunoglobulin Price (USD/Unit) by Application (2020-2031)
 Figure 59. Human Hepatitis B Immunoglobulin Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Feline Infectious Peritonitis (FIP) Antivirals Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4U20267
Mon Nov 24 00:00:00 UTC 2025

Add to Cart

Global Anticoccidial Solutions Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-16R16865
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Bacterial Enteric Disease Testing Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-3F17301
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Whooping Cough Vaccination Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-4B20221
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions